Landmark trials such as RE-LY demonstrate Boehringer Ingelheim's commitment to improving future treatment options for patients. Pradaxa is the most advanced novel oral anticoagulant in clinical development for stroke prevention in atrial fibrillation and our ongoing extensive RE-VOLUTION clinical trial programme is investigating Pradaxa across several further therapeutic areas.
















